Myriad Genetics, Inc.
Myriad Genetics, Inc.
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations | Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | Phase 4 | 2026-04-21 | NCT05457257 | |
| A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 3 | 2026-03-10 | NCT02655016 | |
| SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells | Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasm, skin disorder | Recruiting | Phase 1 | 2026-01-29 | NCT04150042 | |
| Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, hereditary disease, hereditary neoplastic syndrome, neoplasm | Recruiting | Not applicable | 2025-12-26 | NCT07052266 | |
| SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | Solid Tumor | Active, not recruiting | Phase 2 | 2025-10-14 | NCT05642780 |